Results 121 to 130 of about 72,428 (200)

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet, 2017
J. Bruix, S. Qin, P. Merle, A. Granito, Yi‐Hsiang Huang, G. Bodoky, M. Pracht, O. Yokosuka, O. Rosmorduc, V. Breder, R. Gérolami, G. Masi, P. Ross, T. Song, J. Bronowicki, I. Ollivier-Hourmand, M. Kudo, A. Cheng, J. Llovet, R. Finn, M. Leberre, A. Baumhauer, G. Meinhardt, G. Han   +23 more
semanticscholar   +1 more source

Impact of Surgical Resection on Hepatocellular Carcinoma Following Systemic Drug Therapy: A Multicenter Retrospective Observational Study

Hepatology Research, EarlyView.
ABSTRACT Aim This study is aimed to evaluate the safety and outcomes of surgical resection in patients with hepatocellular carcinoma (HCC) treated with systemic therapy, address the therapeutic benefit, and identify candidates for surgery after systemic treatment.
Takamichi Ishii, Junichi Shindoh, Ikuo Nakamura, Seiko Hirono, Masaki Wakasugi, Akihiko Ichida, Takashi Hamada, Hajime Matsushima, Takahiro Nishio, Yukio Tokumitsu, Hidenori Takahashi, Yuji Morine, Shinichiro Yamada, Akiyoshi Nakakura, Susumu Eguchi, Kiyoshi Hasegawa, Etsuro Hatano   +16 more
wiley   +1 more source

Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil‐Mediated Lung Metastasis in Hepatocellular Carcinoma

Advanced Science
Rapid development of resistance to sorafenib and subsequent hyperprogression in patients with advanced hepatocellular carcinoma (HCC) pose significant challenges, with the underlying mechanisms still largely unknown.
Xu‐Yan Wang, Yuan Liao, Rui‐Qi Wang, Yi‐Tong Lu, Ying‐Zhe Wang, Yu‐Qi Xin, Dong‐Ming Kuang, Xiang‐Ming Lao, Junying Xu, Zhi‐Ling Zhou, Kunhua Hu   +10 more
doaj   +1 more source

Efficacy and Safety of Hypofractionated Radiation Therapy Combined With Immunotherapy for Hepatocellular Carcinoma With Vp4 Portal Vein Tumor Thrombosis

Hepatology Research, EarlyView.
ABSTRACT Background Hepatocellular carcinoma (HCC) with Vp4 portal vein tumor thrombosis (PVTT) has an extremely poor prognosis, and evidence for effective systemic therapy is limited. Preclinical studies suggest that hypofractionated radiation therapy (HFRT) may enhance immune checkpoint inhibitor (ICI) efficacy through immunogenic cell death and ...
Masahiko Tameda, Hideaki Tanaka, Yutaka Toyomasu, Mizuki Kawachi, Hirono Owa, Mone Tsukimoto, Yasuyuki Tamai, Naoto Fujiwara, Ryuta Shigefuku, Suguru Ogura, Yoshihito Nomoto, Hayato Nakagawa   +11 more
wiley   +1 more source

Primary and Secondary Grzybowski’s Generalized Eruptive Keratoacanthoma: A New Perspective on Management, Clinical Features, and Prognosis

International Journal of Dermatology, EarlyView.
ABSTRACT Grzybowski's generalized eruptive keratoacanthoma (GEKA) is a rare variant of keratoacanthomas, characterized by hundreds to thousands of lesions, accompanied by pruritus, mucosal involvement, and comorbidities. Our aim was to analyze the clinical presentation, associated comorbidities, treatment strategies, and outcomes of GEKA.
Nicholas Florin Kormos, Carina Maria Petrenciu, Alin Stefan Vizitiu, Raluca Ghețe, Umer Nadir, Adrian Lucian Baican, Stanislav N. Tolkachjov   +6 more
wiley   +1 more source

Sorafenib in advanced clear-cell renal-cell carcinoma.

New England Journal of Medicine, 2007
B. Escudier, T. Eisen, W. Stadler, C. Szczylik, S. Oudard, M. Siebels, S. Négrier, C. Chevreau, E. Solska, A. Desai, F. Rolland, T. Demkow, Thomas E. Hutson, M. Gore, S. Freeman, B. Schwartz, M. Shan, R. Simantov, R. Bukowski   +18 more
semanticscholar   +1 more source

Regorafenib‐Induced Hand‐Foot Skin Reaction in an Adolescent

Pediatric Dermatology, EarlyView.
ABSTRACT Regorafenib is a multikinase inhibitor commonly used in the management of hepatocellular carcinoma, gastrointestinal stromal tumors (GIST), and colorectal cancer. It is also used off‐label for progressive or metastatic osteosarcoma, which is the most common primary bone malignancy in children and adolescents.
Kiera Murphy, Bansri Patel, Shantelle Griffith, Thomas N. Helm   +3 more
wiley   +1 more source

Sorafenib-Induced Interstitial Pneumonitis in a Patient with Hepatocellular Carcinoma: A Case Report

Gut and Liver, 2010
Sorafenib is an oral multikinase inhibitor that has shown a survival benefit in patients with advanced hepatocellular carcinoma, and is considered to be generally safe.
doaj   +1 more source

Harnessing blue light photobiomodulation for cancer therapy: Evidence from a systematic review

Photochemistry and Photobiology, EarlyView.
Conventional treatments for various types of cancer are often associated with tumor recurrence and aggressiveness. Photobiomodulation with blue light (BL; 450–470 nm) emerges as a promising alternative with antitumor effects. This systematic review, with 37 in vitro and in vivo studies from 2002 to 2024, revealed that BL reduces cell viability ...
Bárbara Evelyn Santos de Lima, Rebeca Barros Nascimento, Ana Paula Mariano Santos Ginez, Maria Stella Moreira, Rebeca Boltes Cecatto, Rodrigo Labat Marcos, Maria Fernanda Setúbal Destro Rodrigues   +6 more
wiley   +1 more source

Intracellular magnetic hyperthermia reverses sorafenib resistance in hepatocellular carcinoma through its action on signaling pathways

iScience
Summary: Sorafenib, a first-line drug for advanced hepatocellular carcinoma (HCC), unfortunately encounters resistance in most patients, leading to disease progression.
Hugang Li, Zirui Ye, Xun Wang, Jianlan Yuan, Jingyi Guo, Chen Liu, Bin Yan, Haiming Fan, Yi Lyu, Xiaoli Liu   +9 more
doaj   +1 more source